Secondary hyperparathyroidism (SHPT) is a common and early complication of chronic kidney disease (CKD). Patients with uncontrolled SHPT have high parathyroid hormone (PTH) levels due to mineral metabolism disturbances of several biochemical parameters. These elevated PTH levels put patients at an increased risk of cardiovascular disease and bone fractures. This infographic explores the current treatments available to treat mineral bone disease in CKD (CKD-MBD) and their failure to achieve balance across key disease parameters.
The publication of this infographic was funded by CSL Vifor.
This page is intended for healthcare professionals in Germany and Switzerland only.
